# Immatics N.V. is the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.

*biotech · news · 2026-04-21 · The Manila Times*

## Key points

- Immatics will present four oral abstracts at the 2026 ASCO Annual Meeting, all selected for talks.
- Phase 1b data on anzu-cel in advanced melanoma focuses on characterizing patient-level response dynamics.
- IMA203CD8 showed updated dose-escalation and dose-expansion results in gynecologic cancers at clinically relevant levels.
- Updated Phase 1 data reveals PRAME cell therapies' potential to treat synovial sarcoma beyond melanoma.
- First-in-human results for the MAGEA4/8 bispecific IMA401 suggest combination potential with PRAME bispecific IMA402.

**Companies:** Immatics N.V.
**Countries:** United States, Germany

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/21/tmt-newswire/globenewswire/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting/2325236)

---

Canonical: https://newsio.io/n/c9beb121-172a-4d93-bbe8-01c60e505582/immatics-n-v-is-the-global-leader-in-precision-targeting-of-prame-with-multiple
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works